|
Market Closed -
Nasdaq
16:00:00 2026-09-10 EDT
|
5-day change | 1st Jan Change | ||
| 27.74 USD | +0.22% |
|
-4.11% | +3.86% |
| 08-25 | Deutsche Bank Adjusts ACADIA Pharmaceuticals PT to $38 From $37, Maintains Buy Rating | MT |
| 08-25 | EU Approves Acadia Pharmaceuticals' Rett Syndrome Drug Daybu | MT |
Company Valuation: ACADIA Pharmaceuticals Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,752 | 2,578 | 5,140 | 3,053 | 4,519 | 4,769 | - | - |
| Change | - | -31.29% | 99.4% | -40.6% | 48% | 5.55% | - | - |
| Enterprise Value (EV) 1 | 3,231 | 2,161 | 4,702 | 2,297 | 3,699 | 3,760 | 3,532 | 3,038 |
| Change | - | -33.12% | 117.56% | -51.14% | 61.02% | 1.66% | -6.07% | -13.99% |
| P/E | -22.2x | -11.9x | -84.6x | 13.5x | 11.6x | 45.8x | 32.3x | 18.2x |
| PBR | 6.95x | 6.44x | 11.9x | 4.17x | 3.66x | 3.53x | 3.06x | 2.56x |
| PEG | - | -0.4x | 1.2x | -0x | 0.2x | -0.6x | 0.8x | 0.2x |
| Capitalization / Revenue | 7.75x | 4.98x | 7.08x | 3.19x | 4.22x | 3.75x | 3.33x | 2.96x |
| EV / Revenue | 6.67x | 4.18x | 6.47x | 2.4x | 3.45x | 2.95x | 2.46x | 1.89x |
| EV / EBITDA | -19.3x | -9.75x | -69.3x | 9.31x | 31.7x | 33x | 17.8x | 8.8x |
| EV / EBIT | -19x | -9.67x | -64.1x | 9.95x | 35.3x | 35x | 20.5x | 9.54x |
| EV / FCF | -25.5x | -19x | 282x | 14.6x | 35.2x | 32.1x | 41.9x | 9.75x |
| FCF Yield | -3.92% | -5.28% | 0.35% | 6.84% | 2.84% | 3.11% | 2.39% | 10.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.05 | -1.34 | -0.37 | 1.36 | 2.3 | 0.6053 | 0.8593 | 1.52 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 484.1 | 517.2 | 726.4 | 957.8 | 1,072 | 1,273 | 1,433 | 1,610 |
| EBITDA 1 | -167.1 | -221.6 | -67.83 | 246.7 | 116.6 | 114 | 198.2 | 345.2 |
| EBIT 1 | -170.4 | -223.6 | -73.38 | 230.8 | 104.8 | 107.3 | 172.2 | 318.5 |
| Net income 1 | -167.9 | -216 | -61.29 | 226.5 | 391 | 105.6 | 156.4 | 283.5 |
| Net Debt 1 | -520.7 | -416.8 | -438.9 | -756 | -819.7 | -1,009 | -1,237 | -1,731 |
| Reference price 2 | 23.34 | 15.92 | 31.31 | 18.35 | 26.71 | 27.74 | 27.74 | 27.74 |
| Nbr of stocks (in thousands) | 160,756 | 161,931 | 164,180 | 166,392 | 169,182 | 172,306 | - | - |
| Announcement Date | 2/28/22 | 2/27/23 | 2/27/24 | 2/26/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 45.73x | 2.95x | 33x | -.--% | 4.77B | |
| 31.44x | 5.66x | 16.96x | 1.03% | 46.38B | |
| -21.25x | 245.77x | -22.82x | -.--% | 44.51B | |
| 33.09x | 3.22x | 13.91x | -.--% | 42.3B | |
| 45.98x | 5.31x | 29.05x | -.--% | 39.91B | |
| 27.78x | 8.36x | 21.2x | 0.41% | 32.79B | |
| 33.34x | 5.46x | 24.79x | -.--% | 16.36B | |
| 23.65x | 2.07x | 8.96x | 1.13% | 14.31B | |
| 74.46x | 3.94x | 15.27x | -.--% | 13.29B | |
| Average | 32.69x | 31.42x | 15.59x | 0.29% | 28.29B | |
| Weighted average by Cap. | 26.51x | 47.17x | 12.21x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ACAD Stock
- Valuation ACADIA Pharmaceuticals Inc.
Select your edition
All financial news and data tailored to specific country editions
